Open original FDA record ↗Recall record
- FDA identifier
- Z-1296-2019
- Company in FDA record
- Abbott Laboratories, Inc
- FDA record creation date
- May 8, 2019
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
There is a potential to generate falsely elevated serum or plasma chloride results when using the product.
Source facts
- Action
- The recalling firm issued letters dated 8/28/2018 via overnight mail. The letter explained the issue, patient impact, and instructed the consignee to immediately discontinue use of the product and destroy any remaining inventory of the impacted lot number. The letter was to be reviewed with the Medical Director and laboratory protocol should be followed regarding the need to review previously-reported patient results. A Customer Reply Form was enclosed for the U.S. consignees to indicate the consignee understood and completed the necessary actions to be taken. For questions regarding this information, U.S. Customers please contact Customer Service at 18774ABBOTT (available 24 hours a day, 7 days a week). Customers outside the U.S., please contact your local area Customer Service.
- Initiated
- 2018-08-28
- Root cause
- Under Investigation by firm
- Terminated
- 2020-09-23
- Distribution
- Worldwide Distribution - US Nationwide in the states of AR, CA, CT, FL, IA, IN, LA, MA, MD, MS, NJ, NY, PA, SC, TX, VT, WA, and WV. There was government distribution and no military distribution. Foreign distribution was made to Australia, China, Hong Kong, and New Zealand.
- Recall number
- Z-1296-2019
- Recall status
- Terminated
- CDRH record ID
- 170152
- FDA record created
- 2019-05-08
- Recall event number
- 81861